secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARDELYX, INC. (ARDX)
CIK:        0001437402
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0001628280-22-012619
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ardelyx reports Q1 2022 net loss of $28.1M; first IBSRELA sales of $0.5M
------------------------------------------------------------------------

- First commercial sales of IBSRELA for IBS-C generated $0.5M in March 2022.
- Net loss $28.1M ($0.21 per share) vs $33.2M ($0.34 per share) YoY improvement.
- Cash & investments $89.7M at March 31, 2022, down from $116.7M at Dec 31, 2021.
- FDA to convene advisory committee for XPHOZAH (phosphate binder) for hyperphosphatemia in CKD on dialysis.
- Amended Kyowa Kirin deal: up to $40M additional milestones; royalty rate reduced from high teens to low double digits.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1437402/000162828022012619/0001628280-22-012619-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1437402/000162828022012619/ardx-20220505.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-012619

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer